Literature DB >> 6136006

A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor.

W B Wehrenberg, P Brazeau, R Luben, N Ling, R Guillemin.   

Abstract

Rats were passively immunized with an antiserum against somatostatin and a monoclonal antibody against rat hypothalamic growth hormone-releasing factor (rGRF-mAb) which does not recognize the biologically active 1-40 amino acid fragment of hpGRF-44 (hpGRF-40). Using this paradigm we have observed that the pituitary possesses a resilient capacity to release growth hormone (GH) following repeated injections of hpGRF-40 and that this response follows a dose-dependent relationship.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6136006     DOI： 10.1159/000123504

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN： 0028-3835            Impact factor:   4.914


  3 in total

1.  Human pancreatic tumor GH-releasing factor.

Authors:  M O Thorner; W S Evans; M Vance; J L Borges; R M Blizzard; A D Rogol; R M MacLeod; M J Cronin; L A Frohman; J L Thominet
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

2.  The effects of a continuous infusion of hexarelin on pulsatile growth hormone release, growth axis and galanin gene expression and on the response of the growth axis to growth hormone-releasing hormone.

Authors:  L K Conley; R S Brogan; A Giustina; W B Wehrenberg
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

3.  Synthetic growth hormone-releasing hormone (GHRH 1-44) in the differential diagnosis between hypothalamic and pituitary GH deficiency.

Authors:  M Bozzola; L Tatò; M Cisternino; C Nava; A Valtorta; M Chiesa; F Severi; D Gaburro
Journal:  J Endocrinol Invest       Date:  1986-12       Impact factor: 4.256
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.